CBA Florida Inc. (fka CBAI)

[locksflooring]

READ THIS and weep! AXM Pharma Appoints Ogilvy & Mather Public Relations, Further Expands Marketing Resources
(CBAIs Partner)

AXM Pharma, Inc. announced today that the Company appointed Ogilvy & Mather Public Relations to provide marketing communication support for new marketing, sales and distribution programs being implemented for all products.
Ogilvy Public Relations (PR) is the largest Public Relations Firm in China by billings and employs a professional staff of more than 80 persons. Ogilvy PR is a member of the Ogilvy & Mather Group of companies.

Ogilvy & Mather China http://www.ogilvy.com.cn/about_ogilvy_china/home.html)">; employs more than 800 staff in various marketing functions and works for 9 of the top 20 Fast Moving Consumer Goods Firms and Pharmaceutical Firms. Scott Kronick, Managing Director of Ogilvy PR in China said, "AXM has an interesting business model and exciting brands that are just starting to take root in China. We love opportunities like this in which we can begin to measure success from the very beginning."

"We are pleased to appoint Ogilvy Public Relations. The appointment of O&M Public Relations is another important step in our strategy of increasing resources and expertise in this fast paced market," said Peter Cunningham, president and CEO of AXM Pharma, Inc. "We believe that our strengths in manufacturing and distribution in China, combined with the significant resources, experience and success of O&M Public Relations will continue to allow us to rapidly increase revenue and market share."

AXM Pharma Inc., http://www.axmpharma.com, through its wholly owned subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang and its predecessor company Shenyang Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating history of approximately 10 years. AXM Shenyang historically has been a manufacturer and distributor of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. AXM Shenyang currently out-sources production and distribution of its products to third parties in China.

For additional information on AXM Pharma Inc, please visit http://www.iccinfo.com or call Investor Communications Company, LLC at [phone].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.